The median survival rate for 97 patients on IL-13 almost doubled from 26 weeks to 44 weeks--and counting.
FORBES: Taking on a Monster
In June of 2001 Herbert received IL-13, one of two experimental drugs that destroy glioblastomas while leaving healthy brain cells intact.
Several patients have survived for more than three years, and the FDA has granted IL-13 rare fast-track designation to accelerate its approval.
The toxin is harmless to healthy brain cells, which lack IL-13 receptors.
The preliminary results for IL-13 and Transmid are far more encouraging.
Both IL-13 and Transmid take a Trojan horse approach.
Like IL-13, Transmid spares healthy cells.
应用推荐
模块上移
模块下移
不移动